- Home
- RCKY vs MOLN Comparison
RCKY vs MOLN Comparison
Compare RCKY & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKY
- MOLN
- Stock Information
- Founded
- RCKY 1932
- MOLN 2004
- Country
- RCKY United States
- MOLN Switzerland
- Employees
- RCKY N/A
- MOLN N/A
- Industry
- RCKY Shoe Manufacturing
- MOLN
- Sector
- RCKY Consumer Discretionary
- MOLN
- Exchange
- RCKY Nasdaq
- MOLN Nasdaq
- Market Cap
- RCKY 155.9M
- MOLN 138.6M
- IPO Year
- RCKY 1993
- MOLN 2021
- Fundamental
- Price
- RCKY $23.13
- MOLN $3.57
- Analyst Decision
- RCKY Hold
- MOLN
- Analyst Count
- RCKY 1
- MOLN 0
- Target Price
- RCKY $20.00
- MOLN N/A
- AVG Volume (30 Days)
- RCKY 56.4K
- MOLN 1.8K
- Earning Date
- RCKY 07-29-2025
- MOLN 08-25-2025
- Dividend Yield
- RCKY 2.69%
- MOLN N/A
- EPS Growth
- RCKY 2.41
- MOLN N/A
- EPS
- RCKY 1.84
- MOLN N/A
- Revenue
- RCKY $454,939,000.00
- MOLN $2,525,030.00
- Revenue This Year
- RCKY $6.67
- MOLN N/A
- Revenue Next Year
- RCKY $4.25
- MOLN $866.67
- P/E Ratio
- RCKY $12.52
- MOLN N/A
- Revenue Growth
- RCKY N/A
- MOLN N/A
- 52 Week Low
- RCKY $11.93
- MOLN $3.36
- 52 Week High
- RCKY $37.80
- MOLN $12.22
- Technical
- Relative Strength Index (RSI)
- RCKY 59.18
- MOLN 46.42
- Support Level
- RCKY $23.52
- MOLN $3.51
- Resistance Level
- RCKY $24.93
- MOLN $3.60
- Average True Range (ATR)
- RCKY 0.74
- MOLN 0.08
- MACD
- RCKY 0.08
- MOLN -0.01
- Stochastic Oscillator
- RCKY 70.75
- MOLN 28.95
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.